Gleiss Lutz advises medtech pioneer Brainlab on sale of orthopaedic joint reconstruction business to Smith & Nephew

Gleiss Lutz has advised German medical technology manufacturer Brainlab on the sale of its orthopaedic joint reconstruction division to UK medical technology group Smith & Nephew. The parties have agreed not to disclose the purchase price.

Brainlab, headquartered in Munich, develops, manufactures and markets software-driven medical technology, enabling access to advanced, less invasive patient treatments. Brainlab technology powers more efficient treatments in radiosurgery as well as numerous other surgical fields including neurosurgery, orthopaedic, ENT, CMF, spine and trauma. The medium-sized company, which was formed in 1989, employs almost 1,400 people in 18 offices worldwide and with more than 12,850 systems installed in over 100 countries is one of the market leaders in the industry.

Smith & Nephew is a leading medical technology business active in orthopaedics, wound management, trauma, endoscopy and sports medicine. The company, headquartered in London, has more than 16,000 employees working in over 100 countries. Its annual turnover in 2018 was USD 4.9 billion.

The following team of Gleiss Lutz lawyers advised BrainLab on the transaction: Dr. Jan Balssen (partner, corporate/M&A, Munich), Dr. Alexander Molle (partner, IP/IT, Berlin, both lead), Dr. Michael Ilter (Frankfurt), Dr. Olaf Hohlefelder, Stephanie Dausinger (all corporate/M&A, both Munich), Dr. Matthias Schilde (IP/IT, Berlin), Dr. Enno Burk (counsel, medical law, Berlin), Dr. Doris-Maria Schuster (partner), Hauke Darius Wolf (both employment, Frankfurt), Dr. Iris Benedikt-Buckenleib (counsel, Munich, antitrust/merger control), Dr. Stefan Mayer (partner), Dr. Ocka Stumm (both tax, Frankfurt), Anna Karpf (commercial, Stuttgart).